These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17374600)

  • 1. Is valproate encephalopathy under-recognised in older people? A case series.
    Beyenburg S; Back C; Diederich N; Lewis M; Reuber M
    Age Ageing; 2007 May; 36(3):344-6. PubMed ID: 17374600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Valproate-caused encephalopathy].
    Thygesen KS; Wolf P
    Ugeskr Laeger; 2005 Oct; 167(40):3793-4. PubMed ID: 16221398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Valproate-induced hyperammonemic encephalopathy in a patient with Sjögren's syndrome].
    Nakazato Y; Ando S; Yamamoto T; Tamura N; Shimazu K
    Rinsho Shinkeigaku; 2004 Oct; 44(10):682-5. PubMed ID: 15568484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperammonemic encephalopathy associated with valproate acid].
    Osuna MT; Burcet J; Ramió L; Ustrell X; Silva Y; Molins A
    Neurologia; 2003; 18(6):347-50. PubMed ID: 12838456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?
    Latour P; Biraben A; Polard E; Bentué-Ferrer D; Beauplet A; Tribut O; Allain H
    Hum Psychopharmacol; 2004 Apr; 19(3):193-203. PubMed ID: 15079854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Valproate can induce reversible encephalopathy].
    Prakash S; Harbo T; Christensen J
    Ugeskr Laeger; 2015 May; 177(20):945-6. PubMed ID: 26535436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate-associated hyperammonemic encephalopathy.
    Wadzinski J; Franks R; Roane D; Bayard M
    J Am Board Fam Med; 2007; 20(5):499-502. PubMed ID: 17823470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Valproate can induce reversible encephalopathy].
    Prakash S; Harbo T; Christensen J
    Ugeskr Laeger; 2014 Nov; 176(45):. PubMed ID: 25394838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.
    Ristić AJ; Vojvodić N; Janković S; Sindelić A; Sokić D
    Epilepsia; 2006 Dec; 47(12):2183-5. PubMed ID: 17201721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encephalopathy induced by levetiracetam added to valproate.
    Bauer J
    Acta Neurol Scand; 2008 May; 117(5):374-6. PubMed ID: 18081909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different clinical manifestations of hyperammonemic encephalopathy.
    Gomceli YB; Kutlu G; Cavdar L; Sanivar F; Inan LE
    Epilepsy Behav; 2007 Jun; 10(4):583-7. PubMed ID: 17412645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiepileptic drug-induced encephalopathy].
    Hansen N; Finzel M; Block F
    Fortschr Neurol Psychiatr; 2010 Oct; 78(10):590-8. PubMed ID: 20927690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
    Panda S; Radhakrishnan K
    J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
    Gerstner T; Buesing D; Longin E; Bendl C; Wenzel D; Scheid B; Goetze G; Macke A; Lippert G; Klostermann W; Mayer G; Augspach-Hofmann R; Fitzek S; Haensch CA; Reuland M; Koenig SA
    Seizure; 2006 Sep; 15(6):443-8. PubMed ID: 16787750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management.
    Chopra A; Kolla BP; Mansukhani MP; Netzel P; Frye MA
    Gen Hosp Psychiatry; 2012; 34(3):290-8. PubMed ID: 22305367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate increases the risk of valproic acid-induced encephalopathy.
    Noh Y; Kim DW; Chu K; Lee ST; Jung KH; Moon HJ; Lee SK
    Epilepsia; 2013 Jan; 54(1):e1-4. PubMed ID: 22691153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
    Cheng M; Tang X; Wen S; Yue J; Wang H
    Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
    Mehndiratta MM; Mehndiratta P; Phul P; Garg S
    J Pak Med Assoc; 2008 Nov; 58(11):627-31. PubMed ID: 19024136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Valproate sustained release in the treatment of epilepsy].
    Stefan H; Fraunberger B
    Fortschr Neurol Psychiatr; 2005 Nov; 73(11):681-6. PubMed ID: 16283612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Encephalopathies caused by valproate].
    Göbel R; Görtzen A; Bräunig P
    Fortschr Neurol Psychiatr; 1999 Jan; 67(1):7-11. PubMed ID: 10065384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.